Live Breaking Biotech News and Articles

Biotech News Journal

Subscribe to Biotech News Journal: eMailAlertsEmail Alerts newslettersWeekly Newsletters
Get Biotech News Journal: homepageHomepage mobileMobile rssRSS facebookFacebook twitterTwitter linkedinLinkedIn


Biotech Authors: Greg Wind

Related Topics: Biotech News Journal, Pharmaceutical News, Pandemic News

News Item

Swine Flu Stocks are Seeing Their Largest Pullback Yet

Special report identifies unique investing opportunities in Swine Flu outbreak

Weekly Digest announced the publication of a special report on investment opportunities in the connection with the H1N1 "Swine Flu" Outbreak, including updated outlooks for Gilead Sciences, Sinovac Biotech, Dynavax Technologies, Hemispherx BioPharma (Amex: HEB), BioCryst Pharmaceuticals and several others.

After posting large gains throughout 2009, swine flu stocks are seeing their largest pullback yet. For investors looking to position their portfolios for flu season, there are more ways to trade the flu than ever. Investors have large-cap pharmaceutical plays to choose from, and some of the more volatile, small-cap names have proven the efficacy of their drugs, while others are too far behind in their clinical trials to capitalize on the current pandemic.

The report covers these topics and more recent reports:

-- Which small-cap swine flu plays have a real chance of benefiting in the event of a serious H1N1 outbreak and which are riding on the hype?

-- What sets Sinovac apart from other small caps pursuing vaccines and treatments to fight swine flu? How robust is Sinovac's array of products?

-- Is BioCryst likely to see revenue from its flu treatment during this flu season? How does BioCryst's peramivir fare against established drugs Tamiflu and Relenza? What are the downside risks facing BioCryst after its strong run higher?

-- Is Dynavax a real swine flu play? What do Dynavax investors need to know about the company's swine flu efforts?

-- How important is Tamiflu to Gilead's business? What are the mechanics of Gilead's Tamiflu royalty arrangement with Roche? What are the threats to Tamiflu's dominance in the antiviral market?

More Stories By Liz McMillan

News Desk compiles and publishes breaking news stories, press releases and latest news articles as they happen.